IL326708A - 5-halouracil-modified double-stranded nucleic acids and their use in thetreatment of cancer - Google Patents

5-halouracil-modified double-stranded nucleic acids and their use in thetreatment of cancer

Info

Publication number
IL326708A
IL326708A IL326708A IL32670826A IL326708A IL 326708 A IL326708 A IL 326708A IL 326708 A IL326708 A IL 326708A IL 32670826 A IL32670826 A IL 32670826A IL 326708 A IL326708 A IL 326708A
Authority
IL
Israel
Prior art keywords
mir
nucleotide sequence
nucleic acid
modified
stranded nucleic
Prior art date
Application number
IL326708A
Other languages
English (en)
Hebrew (he)
Original Assignee
Univ New York State Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ New York State Res Found filed Critical Univ New York State Res Found
Publication of IL326708A publication Critical patent/IL326708A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/335—Modified T or U
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL326708A 2023-08-22 2024-08-22 5-halouracil-modified double-stranded nucleic acids and their use in thetreatment of cancer IL326708A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363578033P 2023-08-22 2023-08-22
PCT/US2024/043317 WO2025043036A2 (en) 2023-08-22 2024-08-22 5-halouracil-modified double-stranded nucleic acids and their use in thetreatment of cancer

Publications (1)

Publication Number Publication Date
IL326708A true IL326708A (en) 2026-04-01

Family

ID=94732764

Family Applications (1)

Application Number Title Priority Date Filing Date
IL326708A IL326708A (en) 2023-08-22 2024-08-22 5-halouracil-modified double-stranded nucleic acids and their use in thetreatment of cancer

Country Status (7)

Country Link
EP (1) EP4766830A2 (de)
KR (1) KR20260058839A (de)
CN (1) CN121794381A (de)
AU (1) AU2024329501A1 (de)
IL (1) IL326708A (de)
MX (1) MX2026002118A (de)
WO (1) WO2025043036A2 (de)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2428570B1 (de) * 2001-09-28 2018-05-23 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Mikrorna-moleküle
US8546554B2 (en) * 2008-09-25 2013-10-01 Alnylam Pharmaceuticals, Inc. Lipid formulated compositions and methods for inhibiting expression of Serum Amyloid A gene
CA3042401A1 (en) * 2016-11-01 2018-05-11 The Research Foundation For The State University Of New York 5-halouracil-modified micrornas and their use in the treatment of cancer
CN110960683B (zh) * 2018-09-30 2022-05-20 百药智达（北京）纳米生物技术有限公司 含甲氨蝶呤的药物、其制备方法、药物组合物及其应用
US20220145304A1 (en) * 2019-03-14 2022-05-12 The Research Foundation For The State University Of New York Modified micrornas and their use in the treatment of cancer

Also Published As

Publication number Publication date
MX2026002118A (es) 2026-04-01
WO2025043036A3 (en) 2025-03-27
CN121794381A (zh) 2026-04-03
KR20260058839A (ko) 2026-04-29
WO2025043036A2 (en) 2025-02-27
AU2024329501A1 (en) 2026-03-05
EP4766830A2 (de) 2026-07-01

Similar Documents

Publication Publication Date Title
IL321227A (en) Cyanines dissolved in water and their use in nucleic acid sequencing methods
IL317109A (en) Lipid nanoparticles for the delivery of nucleic acids and methods of using them
IL317798A (en) Particles containing double-stranded RNA and their use in agriculture
AU2003243151A8 (en) Nucleic acid and corresponding protein entitled 251p5g2 useful in treatment and detection of cancer
IL286334B1 (en) Modified microRNAs and their use in cancer treatment
IL299783A (en) Sequence-Specific Targeted Transposition, Selection and Sorting of Nucleic Acids
EP4419687A4 (de) Zustandsaktivierbare nukleinsäurekonstrukte und deren verwendungen zur behandlung neurologischer erkrankungen
IL327476A (en) Modified oligonucleotides and methods for using them
CA3302092A1 (en) 5-halouracil-modified double-stranded nucleic acids and their use in thetreatment of cancer
EP4143336A4 (de) Pseudokomplementäre basen bei der genotypisierung und nukleinsäuresequenzierung
IL319688A (en) siRNA compositions and methods targeting alpha-synuclein nucleic acids
IL314724A (en) Improved DNA dendrimers and methods of using them
IL314316A (en) Compounds and their use in cancer treatment
IL320559A (en) Combining transposon-mediated integration and targeted integration of nucleic acids into host cells
GB202304914D0 (en) Nucleic acid molecule and methods
IL313773A (en) Use of NLRP3 oligonucleotide for prevention and/or treatment of inflammatory diseases
CA3269906A1 (en) Nucleic acid regulatory elements for gene expression in the muscle and methods of use
CA3269026A1 (en) Therapeutic nucleic acids and methods of use thereof
HK40086501A (en) Modified short-interfering rna compositions and their use in the treatment of cancer
ZA202301773B (en) Snp marker of gp gene and its application in macrobrachium rosenbergii
IL272389A (en) Kits containing antibodies to PD-L1 and their uses in therapy
CA3277473A1 (en) Amidinourea derivatives and their use in the treatment of cancer
WO2009050730A3 (en) Rnai mediated knockdown of numa for cancer therapy
GB202510787D0 (en) Small activating nucleic acid molecules and uses thereof
CA3308373A1 (en) Modified oligonucleotides and methods of use thereof